Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Orchestra BioMed (Nasdaq: OBIO) announced that on November 24, 2025 its Compensation Committee granted stock options to purchase an aggregate of 151,250 shares of common stock to 12 newly hired employees under the company’s 2025 New Hire Inducement Plan, pursuant to Nasdaq Listing Rule 5635(c)(4).
Per the awards, 25% of each grantee’s options vest on the first anniversary of employment, with the remainder vesting ratably each quarter over the following three years. The company provided these details to comply with Nasdaq disclosure requirements.
Details
News Market Reaction – OBIO
On Nov 28, the first trading day after this news, OBIO closed 1.53% above the previous close.
Data tracked by StockTitan Argus for the Nov 28 session.
Key Figures
- Inducement options
- 151,250 shares
- Stock options granted to new hires on November 24, 2025
- New employees
- 12 employees
- Recipients under 2025 New Hire Inducement Plan
- Initial vesting
- 25%
- Portion of each grant vesting on first work anniversary
- Remainder vesting period
- 3 years
- Remaining options vest quarterly over next three years
Historical Context
-
Cardiology meeting presentations on AVIM Therapy and Virtue SAB programs.
-
Stock option inducement grants disclosed under Nasdaq Rule 5635(c)(4).
-
Participation in late-2025 institutional investor conferences and webcast.
-
Q3 results plus substantial strategic capital extending cash runway into 2027.
-
Planned call on clinical, strategic and financing developments with partners.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW HOPE, Pa., Nov. 26, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) (“Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through strategic partnerships with market-leading global medical device companies, reported today that, on November 24, 2025, the Compensation Committee of the Orchestra BioMed Board of Directors granted stock options to purchase an aggregate of 151,250 shares of the Company’s common stock to 12 newly hired employees. The awards were granted pursuant to the Orchestra Biomed Holdings, Inc. 2025 New Hire Inducement Plan as an inducement material to each new employee entering employment with Orchestra Biomed, in accordance with Nasdaq Listing Rule 5635(c)(4).
Twenty-five percent of the stock options granted to each new employee will vest on the first anniversary of the date such employee commenced employment with the Company, with the remainder vesting ratably each quarter over the following three-year period.
Orchestra Biomed is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).
About Orchestra BioMed
Orchestra BioMed is a biomedical innovation company accelerating high-impact technologies to patients through strategic collaborations with market-leading global medical device companies. The Company’s two flagship product candidates - Atrioventricular Interval Modulation (AVIM) Therapy and Virtue® Sirolimus AngioInfusion™ Balloon (Virtue SAB) - are currently undergoing pivotal clinical trials for their lead indications, each representing multi-billion-dollar annual global market opportunities. AVIM Therapy is a bioelectronic treatment for hypertension, the leading risk factor for death worldwide, and is designed to be delivered as a firmware upgrade to a pacemaker and achieve immediate, substantial and sustained reductions in blood pressure in patients with hypertensive heart disease. The Company has a strategic collaboration with Medtronic, one of the largest medical device companies in the world, for the development and commercialization of AVIM Therapy for the treatment of uncontrolled hypertension in pacemaker-indicated patients. AVIM Therapy has FDA Breakthrough Device Designation for these patients, as well as an estimated 7.7 million total patients in the U.S. with uncontrolled hypertension despite medical therapy and increased cardiovascular risk. Virtue SAB is a highly differentiated, first-of-its-kind drug delivery angioplasty balloon system designed to deliver a proprietary extended-release formulation of sirolimus, SirolimusEFR™, for the treatment of atherosclerotic artery disease, the leading cause of mortality worldwide. Virtue SAB has been granted Breakthrough Device Designation by the FDA for the treatment of coronary ISR, coronary small vessel disease and below-the-knee peripheral artery disease. For further information about Orchestra BioMed, please visit www.orchestrabiomed.com, and follow us on LinkedIn.
Investor Contact:
Silas Newcomb
Orchestra BioMed
Snewcomb@orchestrabiomed.com
Media Contact:
Kelsey Kirk-Ellis
Orchestra BioMed
kkirkellis@orchestrabiomed.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.